← Back to headlines
Merck Exceeds Quarterly Sales Forecasts Driven by Keytruda Growth
Merck (MRK) reported quarterly sales that surpassed forecasts, primarily attributed to the strong performance and growth of its blockbuster drug Keytruda.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
